Fundraising Fox

Catalent

Somerset, US · Delaware corporation · 4 known investors

catalent.com ↗

Catalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.

Advanced ManufacturingBiotechHealthtech

Founders & leadership

JR
John R. ChiminskiExecutive
WJ
Wetteny JosephExecutive
DE
Donald E. Morel Jr.Named on SEC filing
PZ
Peter ZippeliusNamed on SEC filing

Board

JL
Jack L. StahlBoard director
MB
Madhavan BalachandranBoard director
JM
J. Martin CarrollBoard director
RA
Rolf A. ClassonBoard director
RC
Rosemary CraneBoard director
JJ
John J. GreischBoard director
CK
Christa KreuzburgBoard director
GT
Gregory T. LucierBoard director

Investors · 4

Aisling CapitalNew York
Havencrest Capital ManagementDallas
Leonard GreenLos Angeles
Blackstonereported

Reported raises · per SEC filings

Form D private placements

$650M disclosed across 1 of 2 rounds · 2019–2026

▶$650MraisedMay 2019 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John R. ChiminskiExecutive Officer, Director
  • Jack L. StahlDirector
  • Madhavan BalachandranDirector
  • J. Martin CarrollDirector
  • Rolf A. ClassonDirector
  • Rosemary CraneDirector
  • John J. GreischDirector
  • Christa KreuzburgDirector
  • Gregory T. LucierDirector
  • Donald E. Morel Jr.Director
  • Peter ZippeliusDirector
  • Wetteny JosephExecutive Officer
  • Alessandro MaselliExecutive Officer
  • Steven L. FasmanExecutive Officer
Offering amount
$650M
Amount sold
$650M
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Contract486 shared keywordsContract Pharma is a trade media publication covering the pharmaceutical and biopharmaceutical industry, with a focus on contract development and manufacturing (CDMO) topics. It provides industry news, magazine issues, expert interviews, webinars, whitepapers, company directories, and event coverage for professionals in the pharma and biopharma sector.

Companies competing with Catalent for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA) - Simply Wall St Newssimplywall.st · Aug 2026Gov. Evers, WEDC celebrate Catalent’s $45 Million expansion, adding to the state’s booming biohealth sector - Catalentcatalent.com · Jul 2025BioCentury - Feb. 4 Financial Quick Takes: Catalent raises $500M; venture rounds for BenchSci, Lightship, Inatobiocentury.com · Feb 2020Catalent delivers with $871 million biotech IPO | Fortunefortune.com · Jul 2014

Frequently asked questions

What does Catalent do?
Catalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.
Who are Catalent's investors?
Catalent's investors include Aisling Capital, Havencrest Capital Management, Leonard Green, Blackstone.
How much funding has Catalent raised?
Catalent has disclosed $650M raised across 1 of its 2 known rounds.
Where is Catalent headquartered?
Catalent is headquartered in Somerset, US.